Michael H.R. Tolkien (1920-84): a research travelogue

This article will attempt to put together a portrait of Michael H.R. Tolkien’s life through recent archival and research visits to various locations related to him in the United Kingdom. These visits were conducted during the Spring and Fall of 2015, and while much still needs to be compiled the information as it is currently known, along with the photographs and video footage, provide a unique portrait of Michael H.R. Tolkien never before known. The presentation of the information as it was uncovered is given chronologically, because the volume of research began as an avalanche that affected subsequent tangents and visits, and also because the reader will appreciate the unraveling of the documentation in this manner (almost like a detective story)

The Sounds of Vatican II: Musical Change and Experimentation in Two U.S. Trappist Monasteries, 1965−1984

The Second Vatican Council impacted the use of liturgical music within religious communities. Two U.S. Trappist monasteries, New Melleray Abbey in Dubuque, Iowa, and Gethsemani Abbey in Bardstown, Kentucky, evidenced distinctive approaches to the musical freedom resulting from the Vatican II reforms. New Melleray incorporated contemporary folk music and instruments. At Gethsemani, Father Chrysogonus Waddell pioneered the use of Gregorian notation and English psalmody. The musical changes had a profound effect on the Trappists’ celebration of the Mass and the praying of the Liturgy of the Hours

Reviews

Stories About Stories: Fantasy and the Remaking of Myth. Brian Attebery. Reviewed by David Bratman. The Body in Tolkien\u27s Legendarium: Essays on Middle-earth Corporeality. Edited by Christopher Vaccaro. Reviewed by Janet Brennan Croft. Critical Essays on Lord Dunsany. S.T. Joshi, ed. Lanham MD. Reviewed by Tiffany Brooke Martin. History, Guilt, and Habit. Owen Barfield. Reviewed by Bradford Lee Eden. In the Nameless Wood: Explorations in the Philological Hinterland of Tolkien\u27s Literary Creations. J.S. Ryan. Edited by Peter Buchs. Reviewed by Andrew Higgins. The Letters of Ruth Pitter: Silent Music. Edited by Don W. King. Reviewed by Joe R. Christopher

Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation

Atrial fibrillation affects more than 33 million people worldwide and increases the risk of stroke, heart failure, and death. Fourteen genetic loci have been associated with atrial fibrillation in European and Asian ancestry groups. To further define the genetic basis of atrial fibrillation, we performed large-scale, trans-ancestry meta-analyses of common and rare variant association studies. The genome-wide association studies (GWAS) included 17,931 individuals with atrial fibrillation and 115,142 referents; the exome-wide association studies (ExWAS) and rare variant association studies (RVAS) involved 22,346 cases and 132,086 referents. We identified 12 new genetic loci that exceeded genome-wide significance, implicating genes involved in cardiac electrical and structural remodeling. Our results nearly double the number of known genetic loci for atrial fibrillation, provide insights into the molecular basis of atrial fibrillation, and may facilitate the identification of new potential targets for drug discovery

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe